E
EGBOT
Guest
ART trial: Adacolumn shows clinical benefit in refractory ulcerative colitis patients
Source: ART trial: Adacolumn shows clinical benefit in refractory ulcerative colitis patients
HTML:
Data from the 48-week ART trial, presented today at the Digestive Disease Week meeting, showed that remission and response rates were 37.2% and 53.2% respectively at week 12, in patients with moderate-to-severe, steroid-dependent active ulcerative colitis (UC) with insufficient response or intolerance to immunosuppressants and / or biologics when treated with between five and eight sessions with Adacolumn.Source: ART trial: Adacolumn shows clinical benefit in refractory ulcerative colitis patients
